BBS3 Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of BBS3 monoclonal antibodies for research in understanding Bardet-Biedl Syndrome and its associated pathways. BBS3 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). BBS3, also known as BBS protein 3, plays a critical role in ciliary function and is implicated in the regulation of cellular signaling pathways. Mutations in the BBS3 gene can lead to defects in cilia, contributing to the development of Bardet-Biedl Syndrome, which is characterized by obesity, retinal degeneration, and renal abnormalities. Understanding BBS3 function is essential for elucidating the molecular mechanisms underlying this syndrome and developing potential therapeutic strategies. Researchers worldwide rely on BBS3 monoclonal antibodies to investigate protein expression patterns and interactions in various cellular compartments. Current studies focusing on BBS3 continue to reveal new insights into ciliopathies and their impact on human health. Santa Cruz Biotechnology monoclonal antibodies for BBS3 support researchers in advancing scientific understanding of Bardet-Biedl Syndrome and contributing to the development of targeted therapies.